LCN2 and neoplasm: The relationship between TNBC and Lcn-2 was studied, whereby a tumor-targeted nanolipogel (tNLG) successfully knocked out Lcn-2 via the CRISPR technique from human TNBC cells, leading to a significant decrease in TNBC aggressiveness via modulation of epithelial-to-mesenchymal transition and migration, which resulted in an overall smaller tumor growth [140].